As real-world evidence (RWE) increasingly shapes competition in the relapsing multiple sclerosis (RMS) market, TG Therapeutics is leaning on patient-reported outcomes to carve out space for Briumvi (ublituximab) in a crowded anti-CD20 monoclonal antibody (mAb) field. There is growing importance on patient-centered outcomes as manufacturers seek competitive advantage beyond comparable clinical efficacy in MS treatment, according to GlobalData, a leading data and analytics company, according to GlobalData, a leading intelligence and productivity platform.

At the 12th Congress of the European Academy of Neurology (EAN) 2026, TG Therapeutics has shared the interim results on the real-world treatment satisfaction and quality of life of patients treated with Briumvi (ublituximab) for RMS from the BRILL study.

The BRILL study, an ongoing non-interventional, prospective, multicenter study across Germany, Austria, and Switzerland, reported high treatment satisfaction, stable quality of life, and substantially reduced relapse activity after up to three doses of Briumvi at Week 24. Infusion-related reactions declined with successive infusions, consistent with and comparing favorably to the pivotal ULTIMATE I and II trials, with headaches and chills remaining the most common reactions.

Christie Wong, Managing Neurology Analyst at GlobalData, comments: “Ublituximab is the most recent anti-CD20 monoclonal antibody (mAb) to receive approval for the treatment of MS, in the US in 2022 and in the EU in 2024, following Roche/Genentech’s Ocrevus (ocrelizumab) and Novartis’s Kesimpta (ofatumumab), and competes within a drug class where therapies are differentiated by route of administration, dosing frequency, and treatment setting.”

Key opinion leaders (KOLs) previously interviewed by GlobalData viewed anti-CD20 mAbs as broadly comparable on disease control and reduction of annual relapse rates (ARR) in patients with RMS.

But a key gap across the anti-CD20 mAbs in the MS landscape is the lack of robust, head-to-head real-world comparisons incorporating standardized patient-reported outcomes. While individual studies suggest a generally high treatment satisfaction across the mAbs, the heterogenicity of the studies limits meaningful cross-trial benchmarking.

Wong adds: “A direct comparative real-world study including treatment discontinuation and persistence rates would strengthen differentiation between the therapies and better inform prescribing decisions in an increasingly crowded anti-CD20 mAb market where patient-centered outcomes are gaining greater strategic importance.”

For Briumvi, a later entrant into a competitive anti-CD20 mAb MS market, real-world data on parameters such as patient treatment satisfaction and quality of life are strategically valuable because differentiation on efficacy alone is becoming more challenging.

Wong concludes: “Patient-centered outcomes including treatment convenience, satisfaction, quality of life, and overall treatment burden are becoming more influential in treatment selection. The final BRILL findings could help build a differentiated value proposition for Briumvi centered on the patient experience, an area of growing importance as competition within the anti-CD20 mAbs intensifies.”